Genital Lichen Sclerosus - Epidemiology, Comorbidities and the Role of Vulvar and Penile Microbiome
Study Details
Study Description
Brief Summary
In genital LSc, three pathological processes are implicated in disease development:
inflammation, sclerosis/fibrosis and neoplasia. The role of genital microbiome is still to be investigated and explained. Genital LSc microbiome studies are missing. The ecological community of microorganisms that are present on our body and of the body itself defines the human skin microbiome. Revealing the genital microbiome may potentially lead to new therapies of genital LSc. The primary aim is to analyze genital microbiome before and after the treatment (topical corticosteroids or topical calcineurin inhibitors or circumcision) in both male and female patients diagnosed with genital LSc as well as to analyze genital microbiome in healthy (non-genital LSc) controls. 2) The secondary aim is to determine incidence and prevalence of male and female genital LSc in Sweden and its association with other diseases. The Study will be divided in two parts
-
PART A: Prospective case control study on the effect of treatment on the genital skin microbiome of patients with genital LSc and on the role of genital microbiome in treatment resistance of genital LSc
-
PART B: Swedish nationwide register-based cohort study to analyse incidence, prevalence and comorbidities of genital LSc
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
PART A: Microbiome study The participants will be included continuously at the Dermatology clinic in connection with the regular doctor's visit. All cases included will be asked to complete Dermatology Life Quality Index (DLQI) questionnaires. A first cotton swab sample will be taken from a penile affected skin (including glans penis and coronal sulcus) in men with genital LSc before treatment and from vulvar affected skin (including mons pubis, labia minora and labia majora) in women with genital LSc before treatment. A second cotton swab sample will be taken from the same sites at week 12 after the treatment including both topical therapies and circumcision. The topical treatment will be discontinued a week prior to visit. Allowed treatment options include topical and systemic corticosteroids and topical calcineurin inhibitors (tacrolimus, pimecrolimus) for both sexes and circumcision for men. In extreme resistant cases of genital LSc in women even methotrexate, hydroxychloroquine will be recommended as systemic treatment. The samples will be analyzed using 16S ribosomal RNA metagenomic sequencing to identify the microbiome. Microbio analysis at Laboratory Medicine, Ryhov is today an established method based on "next generation sequencing" (NGS) for analysis of 16S rDNA, which has previously been used for analysis of skin and throat samples in psoriasis projects as well as intestinal biopsies and faecal samples from patients with inflammatory bowel disease. The microbial skin flora is sampled using a microbial swab (eNAT, Copan). Taxonomic classification and a determination of numbers per sample of each taxonomic unit is made on the basis of a reference database (Silva; https://www.arb-silva.de/) and suitable bioinformatics analysis tools such as QIIME2 (https://qiime2.org/) and mothur (https://mothur.org/). Group differences are examined with generalized linear models adapted for number data (eg DESeq2 and glue; https://bioconductor.org/) in the statistical programming environment R (https://cran.r-project.org/), and the analyzes are corrected based on gender and age. The biochemical properties of the microbiome are predicted using reference genomes based on the 16S composition of the samples using PICRUSt2 (https://github.com/picrust/picrust2/wiki), and examined for group differences.
PART B:
-
A retrospective nationwide cohort study will be conducted using national Swedish registers (National Patient Register, Swedish Cancer Register) and LISA database (Longitudinal integration database for health insurance and labor market studies). The patients diagnosed with LSc (ICD-10 diagnosis code - L90) during 20-years period between January 1, 2001 and January 1, 2021 will be selected.
-
Comorbidity will be determined.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| cases women LSc women with LSc- vulvar lesional skin (including mons pubis, labia minora and labia majora) in women with genital LSc |
|
| cases men LSc men with LSc -penile lesional skin (including glans penis and coronal sulcus) in men with genital LSc |
|
| control women women without genital disease |
|
| control men men without genital disease |
Outcome Measures
Primary Outcome Measures
- Quality of life in patients with genital lichen sclerosus (The Dermatology Life Quality Index -DLQI) [24 months]
DLQI questionnaire data will be analysed, the DLQI score will be calculated 0-30 (higher the score, more effect on patient´s quality of life)
- The role of genital microbiome in the treatment resistance of genital LSc [24 months]
analysis of genital microbiome will be performed, 16S ribosomal RNA metagenomic sequencing will be conducted on samples.
- Lichen slerosus comorbidity will be determined in a register study [24 months]
A retrospective nationwide cohort study will be conducted using national Swedish registers (National Patient Register, Swedish Cancer Register) and LISA database (Longitudinal integration database for health insurance and labor market studies). The patients diagnosed with LSc (ICD-10 diagnosis code - L90) during 20-years period between January 1, 2001 and January 1, 2021 will be selected
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age over 18
-
Genital LSc diagnosed by a dermatologist (cases) and individuals without genital LSc (controls)
Exclusion Criteria:
-
Age under 18
-
Pregnancy
-
Current diagnosis of cancer or ongoing treatment for cancer (not applicable for basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of extra-genital localization)
-
Male patients already underwent circumcision as LSc treatment before inclusion into the study
-
Ongoing systemic anti-inflammatory and/or immunomodulating treatment or having discontinued such treatment within the last week
-
Ongoing treatment with systemic antibiotics or having discontinued such treatment within the last week
-
Treatment with topical antibiotics, topical corticosteroids and/or topical calcineurin inhibitors (tacrolimus, pimecrolimus) on the sampling area within the last week
-
Having used antiseptics and disinfectants on the sampling area 24 hours prior to the samples being taken
-
Persons not understanding Swedish or not being able to leave consent to participate
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Department of Dermatology Ryhov County Hospital (Hudkliniken Länssjukhus Ryhov) | Jönköping | Sweden | 55439 |
Sponsors and Collaborators
- Region Jönköping County
- FORSS, Forskningsrådet i Sydöstra Sverige
- Futurum - Academy for health and care
Investigators
- Study Chair: Oliver Seifert, PhD AssProf, Länssjukhuset Ryhov, Hudkliniken
- Study Chair: Jan Söderman, PhD AssProf, Länssjukhuset Ryhov, Division of Microbiology
- Principal Investigator: sandra j gulin, PhD, Länssjukhuset Ryhov, Hudkliniken
- Study Chair: Annika Bergman, PhD, Länssjukhuset Ryhov, Division of Microbiology
- Study Chair: Linda Berglind, Länssjukhuset Ryhov, Division of Microbiology
- Study Chair: Charlotta Enerbäck, PhD Prof, Department of Biomedical and Clinical Sciences, Faculty of Health Sciences, Linköping University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- EPM 2020-xxxxx